Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855049 | 1.00 | FFAR1 (0.44) | FFAR1HCRTR1HCRTR2KMT2AFABP5 | |
| SCHEMBL2564462 | 1.00 | FFAR1 (0.44) | FFAR1HCRTR1HCRTR2KMT2AFABP5 | |
| SCHEMBL25177921 | 1.00 | FFAR1 (0.44) | FFAR1HCRTR1HCRTR2KMT2AFABP5 | |
| SCHEMBL29401491 | 0.96 | FFAR1 (0.47) | FFAR1KMT2AFABP5FABP7PPARG | |
| SCHEMBL20590863 | 0.96 | FFAR1 (0.47) | FFAR1KMT2AFABP5FABP7PPARG | |
| SCHEMBL29855161 | 0.96 | FFAR1 (0.47) | FFAR1KMT2AFABP5FABP7PPARG | |
| SCHEMBL23723017 | 0.96 | FFAR1 (0.47) | FFAR1KMT2AFABP5FABP7PPARG | |
| SCHEMBL119493 | 0.96 | FFAR1 (0.47) | FFAR1KMT2AFABP5FABP7PPARG | |
| SCHEMBL29989803 | 0.96 | FFAR1 (0.47) | FFAR1KMT2AFABP5FABP7PPARG | |
| SCHEMBL29855051 | 0.96 | FFAR1 (0.47) | FFAR1KMT2AFABP5FABP7PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230080520-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2023-03-16 | — | — | US | disclosed |
| US-9782454-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160045572-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2016-02-18 | — | — | US | disclosed |
| EP-2968469-A2 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | Longevity Biotech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150051141-A9 | Compositions Comprising Glucagon Analogs And Methods Of Making And Using The Same | LONGEVITY BIOTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2014145718-A2 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140121154-A1 | Compositions Comprising Glucagon Analogs And Methods Of Making And Using The Same | LONGEVITY BIOTECH, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2694095-A1 | COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME | Longevity Biotech, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20130096050-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2012138941-A1 | COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2011133948-A2 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FFAR1 3629/4885HCRTR1 4185/4885HCRTR2 4324/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FFAR1 3629/4885HCRTR1 4185/4885HCRTR2 4324/4885 |
| US-20230080520-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | FFAR1 38/4885HCRTR1 1468/4885HCRTR2 2044/4885 |
| US-20160045572-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | FFAR1 38/4885HCRTR1 1468/4885HCRTR2 2044/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | FFAR1 3115/4885HCRTR1 3208/4885HCRTR2 3422/4885 |
| US-20150051141-A9 | Compositions Comprising Glucagon Analogs And Methods Of Making And Using The Same | GLP1R, IAPP, GIPR | FFAR1 95/4885HCRTR1 762/4885HCRTR2 1159/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | FFAR1 3629/4885HCRTR1 4185/4885HCRTR2 4324/4885 |
| US-20130096050-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | FFAR1 105/4885HCRTR1 1713/4885HCRTR2 2453/4885 |
| US-20140121154-A1 | Compositions Comprising Glucagon Analogs And Methods Of Making And Using The Same | GLP1R, IAPP, GIPR | FFAR1 95/4885HCRTR1 762/4885HCRTR2 1159/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | FFAR1 99/4885HCRTR1 1499/4885HCRTR2 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.